Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Neurogen (NRGN) -- Ignore unavailable to you. Want to Upgrade?

To: HB who wrote (207)	2/4/1999 2:07:00 PM
From: NeuroInvestment	Read Replies (1) \| Respond to of 523

No. I was not suggesting that. I do have some doubts as to how good a predictor the response of normal individuals to induced situational anxiety is of the response of clinical GAD or panic populations, at least in terms of dosing, which was NRGN's stated agenda. However, the lack of any significant difference from placebo does not suggest they should now run a clinical trial with 95-2---and the fact that PFE/NRGN went public with an interim analysis is quite striking. If they thought the rest of the sample might change things, they would not have commented now, so it must have been bleak. NeuroInvestment (www.neuroinvestment.com)